TEST:

Oncomine Precision Assay

The noteworthy observation is out of 7 Triple Negative Breast Cancer patients three patients were negative for any mutation. Hence, the association of genetic variation with clinicopathological parameters will be helpful in the selection of targeted treatment.

ESR1 mutations are detectable in approximately one-third of ER+/HER2- metastatic patients undergoing liquid biopsy. NGS platforms allow for sensitive and in-depth analysis, highlighting co-mutations of potential clinical and therapeutic relevance.

MTAP IHC seems to be better suited than OPA-NGS to assess the MTAP status in NSCLC, especially as the MTAP gene is not specifically covered within this panel. CDKN2A loss is not a reliable MTAP loss surrogate, as it overestimated MTAP loss in more than 25% of the cases in the TCGA cohort.

The comparison revealed high concordance, clinical relevance, and reliability of liquid biopsy-based genomic profiling in diverse oncologic settings. Study underscores substantial increase in the adoption of liquid biopsy and the real-world utility of ctDNA-based NGS testing in solid tumors contributing to improved patient care management.

The ctDNA assay demonstrates high accuracy and specificity, for both prevalent and rare genetic alterations. While further advancements are needed to enhance sensitivity and routine clinical application, our ctDNA profiling assay offers a reliable alternative for detecting genetic alterations in lung cancer patients, with significant potential for clinical integration in the Indian healthcare context.

The prevalence of EGFR mutations in early stage (IA-IIIB), resectable, non-squamous NSCLC observed in our study is consistent with that reported in advanced NSCLC in Spain. Molecular testing is crucial in early-stage NSCLC and can be performed either with single-gene testing or NGS.

Liquid biopsy holds promise for identifying high-risk lung adenocarcinoma cases and serves as a complementary diagnostic tool in advanced stages, enhancing disease management strategies.

The use of NGS has identified critical genetic mutations, facilitating the development of personalized treatments and improving clinical outcomes. These findings pave the way for future research aimed at refining diagnostic and therapeutic strategies, thereby contributing to better patient management.

P=N/A, N=100, Completed, Exactis Innovation | Recruiting --> Completed

NGS quality control metrics were also comparable between both extraction methods. The overall TAT of the automated NGS workflow from specimen received to test result was 24 hours, providing rapid and reliable molecular results for timely clinical decision-making and improved patient outcomes.

While an increasing cfDNA was associated with worse progression free survival (p < 0.01). cfDNA is a novel biomarker with potential to monitor disease progression in patients with advanced thyroid cancers.

The OPA-GX fully automated NGS platform accurately and reproducibly detects actionable solid-tumor hotspot mutations. Low FFPE DNA and RNA input requirement (10ng) allows for profiling of small tissue specimens that resulted in 100% sequencing success rate. The OPA-GX completes the entire NGS workflow and delivers clinically significant genomic findings in 16 to 20 hours depending on number of tested samples.